Severe early-onset withdrawal reported after mitragynine pseudoindoxyl use

Why it matters

The case shows that concentrated semisynthetic kratom derivatives can produce severe, rapid opioid-like withdrawal that differs from reports tied to traditional leaf products.

The big picture

A 34-year-old man with prior heroin use disorder progressed from powdered kratom to 7-hydroxymitragynine and then mitragynine pseudoindoxyl tablets. The report also describes a treatment course and follow-up.

Key findings

• The patient averaged nine 20 mg MP doses daily; withdrawal reached a Clinical Opiate Withdrawal Scale score of 31; symptoms resolved after 72-96 hours of supportive care; naltrexone was started after an opioid-free interval and he remained abstinent at one month.

What they say

The authors said clinicians should recognize MP’s severe withdrawal profile and the limits of standard toxicology.

Bottom line

**A case report links high-dose mitragynine pseudoindoxyl with severe withdrawal and highlights the need for derivative-specific clinical awareness.**